RxDoctor Payments Data

Luzviminda Nobleza, MD

Psychiatry · Torrance, CANPI 1417972167

Payments from drug & device makers

$4,378in general payments, 2019–2025

Across 260 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$996
  • Alkermes, Inc.$866
  • Sunovion Pharmaceuticals Inc.$655
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$540
  • Teva Pharmaceuticals USA, Inc.$346
  • Johnson & Johnson$280
  • plus $695 from 6 others

What the payments were for

  • Food & beverage$4,31499%
  • Education$641%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,378 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$32,876
Medicare patients
80
Services billed
348

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate38$324,521
VraylarCariprazine Hcl154$223,733
Invega SustennaPaliperidone Palmitate36$136,801
Abilify MaintenaAripiprazole33$93,244
RexultiBrexpiprazole48$68,387
AustedoDeutetrabenazine12$60,436
Aripiprazole OdtAripiprazole32$37,091
LybalviOlanzapine/Samidorphan Malate19$32,783
CaplytaLumateperone Tosylate15$25,995
FanaptIloperidone13$24,551
Lurasidone Hcl170$22,971
Aripiprazole144$20,028
Quetiapine Fumarate ErQuetiapine Fumarate95$16,620
Risperidone OdtRisperidone34$14,183
Divalproex Sodium ErDivalproex Sodium178$10,267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$253$324,52138 claims
AbbVieVraylar, Fetzima$996$233,241174 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$182$161,63081 claims
Johnson & JohnsonInvega Sustenna$280$136,80136 claims
Teva Pharmaceuticals USA, Inc.Austedo$346$60,43612 claims
Alkermes, Inc.Lybalvi$866$32,78319 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$540$25,99515 claims
Vanda Pharmaceuticals Inc.Fanapt$99$24,55113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →